Upcoming Webinars

WEBINAR ARCHIVES

Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating illnesses. Wave has initiated DYSTANCE 51, a global […]
We will provide an update on the scientific rationale for use of vamorolone, and share some results from our open-label Long Term Extension study. The very important pivotal clinical trial is now seeking participants; we will review information about this trial. ReveraGen was recently awarded a grant to study family and physician preferences regarding the […]
On Tuesday, November 12, 2019, from 4:00 PM to 4:30 PM, we learned about the CureDuchenne Biobank, which launched at our 2019 FUTURES national conference and will continue collecting samples at select CureDuchenne events around the country. Topics and their respective speakers, include: An Introduction to our CureDuchenne Biobank and why we created it | […]
The webinar will review the Italfarmaco Givinostat development program for Duchenne and Becker Muscular Dystrophy. Content that will be covered, includes: Updates from the EPIDYS Study, a phase 3 clinical trial of Givinostat in ambulatory boys with DMD. Data from Italfarmaco’s long term studies of Givinostat in DMD populations. 30 minute Q & A. Speakers: […]
In rare diseases such as Duchenne, where the disease population is small, the drug development process can vary from that of more common diseases, and totally new treatment approaches such as gene therapies are emerging. Therefore, it is critical that families accurately understand the process and how they can help support—and possibly benefit from—the development […]
1 2 3 6

Get Involved

Are you a medical professional or provider? Learn more about how you can help make a difference in the Duchenne community.

CLICK HERE